Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Release

Galectin 3 Pipeline Review, H2 2016: 5 Companies & 14 Molecules - Research and Markets

Research and Markets
Posted on: 11 Oct 16

Research and Markets has announced the addition of the "Galectin 3 (35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Proteinor Mac 2 Antigen or LGALS3) - Pipeline Review, H2 2016" report to their offering.

Galectin 3 pipeline Target constitutes close to 14 molecules. Out of which approximately 14 molecules are developed by Companies.

Our latest report Galectin 3 - Pipeline Review, H2 2016, outlays comprehensive information on the Galectin 3 (35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Proteinor Mac 2 Antigen or LGALS3) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Galectin-3 is a protein encoded by the LGALS3 gene. It mediates with the alpha-3, beta-1 integrin the stimulation by CSPG4 of endothelial cells migration. It acts as a pre-mRNA splicing factor. It is involved in acute inflammatory responses including neutrophil activation and adhesion, chemoattraction of monocytes macrophages, opsonization of apoptotic neutrophils, and activation of mast cells. The molecules developed by Companies in Phase II, Preclinical and Discovery stages are 2, 10 and 2 respectively.

Furthermore, this report also reviews key players involved in Galectin 3, targeted therapeutics development, features dormant and discontinued projects and latest news and press releases.

Key Topics Covered:

  1. Introduction
  2. Galectin 3 Overview
  3. Therapeutics Development
  4. Pipeline Products for Galectin 3 - Overview
  5. Pipeline Products for Galectin 3 - Comparative Analysis
  6. Galectin 3 - Therapeutics under Development by Companies
  7. Galectin 3 - Therapeutics under Investigation by Universities/Institutes
  8. Galectin 3 Products Glance
  9. Late Stage Products
  10. Clinical Stage Products
  11. Early Stage Products
  12. Galectin 3 - Products under Development by Companies
  13. Galectin 3 - Products under Investigation by Universities/Institutes
  14. Galectin 3 - Companies Involved in Therapeutics Development
  • Angion Biomedica Corp.
  • Bristol-Myers Squibb Company
  • Galectin Therapeutics, Inc.
  • GlycoMimetics, Inc.
  • MandalMed, Inc.

For more information about this report visit http://www.researchandmarkets.com/research/fjbb2m/galectin_3_35

View source version on businesswire.com: http://www.businesswire.com/news/home/20161011005821/en/

Business Wire
www.businesswire.com

Last updated on: 11/10/2016

Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.